SELLAS Life Sciences Group Inc.
Organization details
- Legal name
- SELLAS Life Sciences Group Inc.
- Former names
- Galena Biopharma, INC. RXI Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SLS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001390478
- Wikidata ID
- Q5518376
Board of directors
-
Angelos M. Stergiou · Director · President and CEOSince 2023
-
David A. Scheinberg · DirectorSince 2023
-
Jane Wasman · DirectorSince 2023
-
John Varian · DirectorSince 2023
-
Katherine Bach Kalin · DirectorSince 2023
-
Nostrand Robert L. Van · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.8%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Rigel Pharmaceuticals Inc. Same sectorvia Jane Wasman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $100,806
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Angelos M. Stergiou Director, Officer (President and CEO) | Grant or award | +1,065,000 | — | — |
| Jan 7, 2026 | John Varian Director | Grant or award | +50,000 | — | — |
| Jan 7, 2026 | Nostrand Robert L. Van Director | Grant or award | +50,000 | — | — |
| Jan 7, 2026 | David A. Scheinberg Director | Grant or award | +50,000 | — | — |
| Jan 7, 2026 | CICIC DRAGAN Officer (SVP, Chief Development Officer) | Grant or award | +300,000 | — | — |
| Jan 7, 2026 | Burns John Thomas Officer (CFO) | Grant or award | +300,000 | — | — |
| Jan 7, 2026 | Katherine Bach Kalin Director | Grant or award | +50,000 | — | — |
| Jan 7, 2026 | Jane Wasman Director | Grant or award | +50,000 | — | — |
| Dec 3, 2025 | CICIC DRAGAN Officer (SVP, Chief Development Officer) | Other | −63,800 | $1.50 | $95,700 |
| Dec 3, 2025 | Burns John Thomas Officer (CFO) | Other | −58,592 | $1.50 | $87,888 |
| Dec 3, 2025 | Angelos M. Stergiou Director, Officer (President and CEO) | Other | −187,066 | $1.50 | $280,599 |
| Nov 19, 2025 | Katherine Bach Kalin Director | Open-market purchase | +63,400 | $1.59 | $100,806 |
| Jun 12, 2025 | Nostrand Robert L. Van Director | Open-market purchase | +10,000 | $1.48 | $14,800 |
| May 30, 2025 | Jane Wasman Director | Open-market purchase | +20,000 | $1.69 | $33,800 |
| May 22, 2025 | Katherine Bach Kalin Director | Open-market purchase | +20,000 | $1.80 | $36,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about SELLAS Life Sciences Group Inc.
Who is the CEO of SELLAS Life Sciences Group Inc.?
Angelos M. Stergiou is SELLAS Life Sciences Group Inc.'s President and CEO.
How many directors are on SELLAS Life Sciences Group Inc.'s board?
SELLAS Life Sciences Group Inc.'s board has 6 directors: Angelos M. Stergiou, David A. Scheinberg, Jane Wasman, John Varian, Katherine Bach Kalin and Nostrand Robert L. Van.
Are SELLAS Life Sciences Group Inc. insiders buying or selling shares?
Over the last 12 months, SELLAS Life Sciences Group Inc. insiders bought $100,806 of shares in 1 purchase and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="sellas-life-sciences-group-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.